Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024
Armata Pharmaceuticals (NYSE American: ARMP), a clinical-stage biotech company, will present at the Viruses of Microbes 2024 conference in Cairns, Australia.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Armata Pharmaceuticals (NYSE American: ARMP), a clinical-stage biotech company, will present at the Viruses of Microbes 2024 conference in Cairns, Australia. The event occurs from July 15-19, 2024. Steven Branston, the Australia Site Head, will deliver a presentation titled 'Advancing Bacteriophage Therapy from Discovery to Clinical Trials' on July 18 at the Phage Therapy Session 2 – Clinical Application. The presentation will cover the progress in bacteriophage therapy, a promising approach for treating antibiotic-resistant bacterial infections.
Positive
- Armata Pharmaceuticals' participation in a significant conference enhances visibility and credibility in the biotech field.
- Presentation on advancements in bacteriophage therapy could attract investor interest and partnerships.
Negative
- No new financial data or clinical trial results were disclosed, which may lead to investor uncertainty.
Details
News Market Reaction – ARMP
The recorded move for ARMP in the trading session of this news was +11.94%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Details of the presentation are as follows:
Title: | Advancing Bacteriophage Therapy from Discovery to Clinical Trials |
Session: | Phage Therapy Session 2 – Clinical Application |
Presenter: | Steven Branston, Australia Site Head |
Day: | Thursday, July 18 |
Time: | 11:20am-11:40am AEST (9:20pm-9:40pm EDT on Wednesday, July 17) |
For more information: https://www.vom2024.org/ | |
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.
At Armata:
Pierre Kyme
Armata Pharmaceuticals, Inc.
ir@armatapharma.com
310-665-2928
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569
View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-announces-presentation-at-viruses-of-microbes-2024-302191113.html
SOURCE Armata Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.